University of Wisconsin–Madison

Combined Gadoxetic Acid and Gadobenate Dimeglumine Enhanced Liver MRI for Detection and Characterization of Liver Metastases, an Optimization Study

March 2017 to September 2017

The overall goal of this project is to perform a contrast optimization study in healthy volunteers to optimize MR imaging with the hepatobiliary gadolinium based contrast agent, gadoxetic acid, in combination with an intravascular gadolinium based contrast agent, gadobenate dimeglumine. The reason to perform this project is that the intravascular contrast agent used in a previous parameter-optimization study (gadofosveset trisodium), whose protocol had been applied in clinical routine, was taken off the market in August 2016.

This project led by: Gesine Knobloch, MD